A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Public ClinicalTrials.gov record NCT04125836. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.
Study identification
- NCT ID
- NCT04125836
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2019
- Primary completion
- Apr 23, 2025
- Completion
- Apr 23, 2025
- Last update posted
- Dec 21, 2025
2019 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Department of Medicine Division of Endocrinology | Los Angeles | California | 90095 | — |
| Stanford University Medical Center | Palo Alto | California | 94305 | — |
| Prufen Clinical Research LLC | Miami | Florida | 33130 | — |
| University of Michigan | Ann Arbor | Michigan | 48106 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University in St. Louis, School of Medicine | St Louis | Missouri | 63110 | — |
| Palm Research Center | Las Vegas | Nevada | 89148 | — |
| Columbia University Medical Center | New York | New York | 10018 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Allegheny Endocrinology Associates | Pittsburgh | Pennsylvania | 15212 | — |
| Research Institute of Dallas | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04125836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04125836 live on ClinicalTrials.gov.